Cargando…

MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem/progenitor cells that is caused by the Bcr-Abl oncoprotein. Clinical resistance to the Bcr-Abl inhibitor imatinib is a critical problem in treating CML. This study investigated the antitumor effect and mechanism of MPT0B169, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Shuit-Mun, Liu, Fu-Hwa, Lee, Yueh-Lun, Huang, Huei-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729476/
https://www.ncbi.nlm.nih.gov/pubmed/26815740
http://dx.doi.org/10.1371/journal.pone.0148093
_version_ 1782412257815166976
author Wong, Shuit-Mun
Liu, Fu-Hwa
Lee, Yueh-Lun
Huang, Huei-Mei
author_facet Wong, Shuit-Mun
Liu, Fu-Hwa
Lee, Yueh-Lun
Huang, Huei-Mei
author_sort Wong, Shuit-Mun
collection PubMed
description Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem/progenitor cells that is caused by the Bcr-Abl oncoprotein. Clinical resistance to the Bcr-Abl inhibitor imatinib is a critical problem in treating CML. This study investigated the antitumor effect and mechanism of MPT0B169, a new antitubulin agent, in K562 CML cells and their derived imatinib-resistant cells, IMR2 and IMR3. IMR2 and IMR3 cells showed complete resistance to imatinib-induced growth inhibition and apoptosis. Resistance involved ERK1/2 overactivation and MDR1 overexpression. MPT0B169 inhibited the growth of K562, IMR2, and IMR3 cells in a dose- and time-dependent manner. MPT0B169 substantially inhibited the mRNA and protein levels of Bcr-Abl, followed by its downstream pathways including Akt, ERK1/2, and STAT3 in these cells. MPT0B169 treatment resulted in a decrease in the polymer form of tubulin according to Western blot analysis. It triggered cell cycle arrest at the G2/M phase before apoptosis, which was related to the upregulation of the mitotic marker MPM2 and the cyclin B1 level, and a change in the phosphorylation of Cdk1. MPT0B169 induced apoptosis in nonresistant and imatinib-resistant cells via a mitochondrion-mediated caspase pathway. Further study showed that the agent led to a decrease in the antiapoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 and an increase in the apoptotic protein Bax. Taken together, our results suggest that MPT0B169 might be a promising agent for overcoming imatinib resistance in CML cells.
format Online
Article
Text
id pubmed-4729476
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47294762016-02-04 MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells Wong, Shuit-Mun Liu, Fu-Hwa Lee, Yueh-Lun Huang, Huei-Mei PLoS One Research Article Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem/progenitor cells that is caused by the Bcr-Abl oncoprotein. Clinical resistance to the Bcr-Abl inhibitor imatinib is a critical problem in treating CML. This study investigated the antitumor effect and mechanism of MPT0B169, a new antitubulin agent, in K562 CML cells and their derived imatinib-resistant cells, IMR2 and IMR3. IMR2 and IMR3 cells showed complete resistance to imatinib-induced growth inhibition and apoptosis. Resistance involved ERK1/2 overactivation and MDR1 overexpression. MPT0B169 inhibited the growth of K562, IMR2, and IMR3 cells in a dose- and time-dependent manner. MPT0B169 substantially inhibited the mRNA and protein levels of Bcr-Abl, followed by its downstream pathways including Akt, ERK1/2, and STAT3 in these cells. MPT0B169 treatment resulted in a decrease in the polymer form of tubulin according to Western blot analysis. It triggered cell cycle arrest at the G2/M phase before apoptosis, which was related to the upregulation of the mitotic marker MPM2 and the cyclin B1 level, and a change in the phosphorylation of Cdk1. MPT0B169 induced apoptosis in nonresistant and imatinib-resistant cells via a mitochondrion-mediated caspase pathway. Further study showed that the agent led to a decrease in the antiapoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 and an increase in the apoptotic protein Bax. Taken together, our results suggest that MPT0B169 might be a promising agent for overcoming imatinib resistance in CML cells. Public Library of Science 2016-01-27 /pmc/articles/PMC4729476/ /pubmed/26815740 http://dx.doi.org/10.1371/journal.pone.0148093 Text en © 2016 Wong et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wong, Shuit-Mun
Liu, Fu-Hwa
Lee, Yueh-Lun
Huang, Huei-Mei
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title_full MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title_fullStr MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title_full_unstemmed MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title_short MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
title_sort mpt0b169, a new antitubulin agent, inhibits bcr-abl expression and induces mitochondrion-mediated apoptosis in nonresistant and imatinib-resistant chronic myeloid leukemia cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729476/
https://www.ncbi.nlm.nih.gov/pubmed/26815740
http://dx.doi.org/10.1371/journal.pone.0148093
work_keys_str_mv AT wongshuitmun mpt0b169anewantitubulinagentinhibitsbcrablexpressionandinducesmitochondrionmediatedapoptosisinnonresistantandimatinibresistantchronicmyeloidleukemiacells
AT liufuhwa mpt0b169anewantitubulinagentinhibitsbcrablexpressionandinducesmitochondrionmediatedapoptosisinnonresistantandimatinibresistantchronicmyeloidleukemiacells
AT leeyuehlun mpt0b169anewantitubulinagentinhibitsbcrablexpressionandinducesmitochondrionmediatedapoptosisinnonresistantandimatinibresistantchronicmyeloidleukemiacells
AT huanghueimei mpt0b169anewantitubulinagentinhibitsbcrablexpressionandinducesmitochondrionmediatedapoptosisinnonresistantandimatinibresistantchronicmyeloidleukemiacells